drugset / Trial / NCT05517616

The Absorption, Metabolism and Excretion of [14C]APG-2575 in Healthy Subjects

NCT05517616

Phase 1 Completed 6 enrolled Ascentage Pharma Group Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption properties, as well as to evaluate the mass balance and elucidate the pathways of biotransformation after a single oral dose of 400mg, 200μCi \[14C\] APG-2575 to healthy subjects.

Timeline

Start
2022-09-14
Primary completion
2022-11-01
Completion
2023-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-2575 Small molecule 400 mg Oral

Indications

No indication recorded.